A novel approach to cardiovascular events in patients with systemic lupus erythematosus: risk factor assessment and treatment analysis.

IF 3.2 3区医学 Q2 RHEUMATOLOGY

Rheumatology International Pub Date : 2025-05-10 DOI:10.1007/s00296-025-05894-4

Dorota Suszek, Magdalena Popławska, Jakub Prośniak, Katarzyna Siemieniec, Karolina Przeniosło, Weronika Wallach, Monika Żybowska-Męczyńska, Klaudia Ostrowicz, Anna Rzewuska-Fijałkowska, Bożena Targońska-Stępniak

引用次数: 0

Abstract

Systemic lupus erythematosus (SLE) patients have a significantly increased risk of developing cardiovascular disease (CVD). Despite the implementation of preventive measures and treatment of lipid disorders, as well as reduced use of glucocorticoids, CVD remains one of the leading causes of death in this patient group. It is crucial to develop an appropriate CVD risk assessment strategy that considers the distinctive characteristics of this patient population. This paper provides a comprehensive analysis of the methods used to assess CVD risk in SLE patients. It also presents effective strategies for the reduction of the effects of traditional and non-traditional risk factors for atherosclerosis.

查看原文本刊更多论文

系统性红斑狼疮患者心血管事件的新方法：危险因素评估和治疗分析。

系统性红斑狼疮（SLE）患者发生心血管疾病（CVD）的风险显著增加。尽管实施了预防措施和治疗脂质紊乱，以及减少糖皮质激素的使用，心血管疾病仍然是这一患者群体中死亡的主要原因之一。考虑到这一患者群体的独特特征，制定适当的心血管疾病风险评估策略至关重要。本文全面分析了用于评估SLE患者心血管疾病风险的方法。它还提出了有效的策略，以减少动脉粥样硬化的传统和非传统的危险因素的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Rheumatology International 医学-风湿病学

CiteScore

7.30

自引率

5.00%

发文量

191

审稿时长

16. months

期刊介绍： RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology. RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production. Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.